GENE ONLINE|News &
Opinion
Blog

2022-10-27| R&D

How Genetics Might Affect PTSD Susceptibility

by Nai Ye Yeat
Share To

Stem cell-derived neurons from combat veterans with post-traumatic stress disorder (PTSD) react differently to a stress hormone than those from veterans without PTSD, according to a new finding published October 20 in Nature Neuroscience. The article provided insights into how genetics affect susceptibility to developing PTSD following trauma exposure.

With the collaboration of scientists from the Icahn School of Medicine at Mount Sinai, the James J. Peters Veterans Affairs Medical Center, the Yale School of Medicine, and The New York Stem Cell Foundation Research Institute (NYSCF), the study claims to be the first to use induced pluripotent stem cell (iPSC) models to study this specific mental disorder. 

Related Article: From Forbidden Drugs to Psychotropic Cures: A “Psychedelic Boom” Breaks New Ground in Treating Mental Illnesses

Novel Model to Investigate Genetic Susceptibility of PTSD

PTSD is a mental health condition triggered by experiencing or witnessing a terrifying event. Two people can experience the same trauma, but the two are not guaranteed to develop PTSD, so how genetic and environmental risk factors contribute to individual clinical outcomes remains unknown. To bridge this information gap, the research team studied a cohort of 39 combat veterans with and without PTSD. 

Most similar studies of PTSD to date have used blood samples from patients; however,  since PTSD is rooted in the brain, scientists need a way to capture how the neurons of prone individuals are affected by stress. As pulling neurons from a living person’s brain seems impossible, the team opted to use stem cells, as they are uniquely equipped to provide a patient-specific, non-invasive window into the brain. 

In this study, the veterans later underwent skin biopsies, and researchers reprogrammed their skin cells into induced pluripotent stem cells.

Transitioning the Research into Practical Uses

The scientists exposed the iPSC-derived neurons to the stress hormone hydrocortisone, one of our body’s cortisol that is used as part of the “fight-or-flight” response to mimic the stress response that triggers PTSD.

Gene expression profiling and imaging showed that neurons from individuals with PTSD were hypersensitive to this pharmacological trigger. The scientists also identified the specific gene networks that responded differentially following exposure to stress hormones. 

The distinctions between how PTSD and non-PTSD neurons responded to stress could help predict which individuals are at higher risk for PTSD. To help patients with urgent needs, finding already-approved drugs that could reverse the hypersensitivity seen in neurons is essential.

In the future, scientists will leverage the iPSC models to investigate further the genetic risk factors pinpointed by this study while investigating how PTSD affects other types of brain cells. This valuable research would help broaden therapeutic discovery opportunities and provide new treatment alternatives for patients.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Fifth HIV Patient Cured After Stem Cell Transplant in Germany
2023-03-01
Human “Mini-Brains” Transplantation Shows a Way to Cure Blindness
2023-02-09
R&D
Are iPSCs safe? Nearly 75% of Skin Stem Cells Have Severe DNA Damage from UV Exposure
2022-08-29
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top